<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462576</url>
  </required_header>
  <id_info>
    <org_study_id>CON-EX-0217</org_study_id>
    <nct_id>NCT03462576</nct_id>
  </id_info>
  <brief_title>Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17</brief_title>
  <official_title>Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-17</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conatus Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a companion protocol that will use the data generated by Conatus' study of&#xD;
      emricasan under protocol IDN-6556-17.The IDN-6556-17 study is a Phase 2, multicenter,&#xD;
      double-blind, placebo-controlled trial of Emricasan in subjects with decompensated&#xD;
      non-alcoholic steatohepatitis (NASH) cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol is intended to validate the ability of the MBT to predict deterioration by 48&#xD;
      weeks for all subjects, and at later time points for those followed longer, for subjects with&#xD;
      decompensated NASH cirrhosis in the placebo treatment arm of Conatus' study IDN-6556-17.&#xD;
&#xD;
      As one of the Conatus' study secondary objectives, this companion protocol is designed to&#xD;
      assess improvement in liver metabolic function as measured by Methacetin Breath Test (MBT) [&#xD;
      Time Frame: Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) ].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor of Trial decision&#xD;
  </why_stopped>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">July 15, 2019</primary_completion_date>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48. All subjects will continue treatment until the last subject in the study reaches 48 weeks in the study. At least 30% of subjects randomized should have baseline MELD score ≥15 and ≤20.&#xD;
For each subject, the study will consist of:&#xD;
Screening period of up to 4 weeks&#xD;
Randomized, double-blind treatment period of at least 48 weeks&#xD;
A follow-up visit 2 weeks after completion of study drug treatment The duration of each subject's participation will be at least 54 weeks for those completing the entire study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The collaborator is responsible for the masking process.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Experiencing a High Risk Event Based on a 5.5%/Hour Cut-off</measure>
    <time_frame>1 hour for MBT for assessment of this diagnostic outcome assessed during screening</time_frame>
    <description>Binary diagnosis of subjects that are at high risk to develop a deterioration event as determined by the Methacetin Breath Test (MBT) derived from an algorithm developed under other Exalenz clinical studies using a pre-designed cutoff of Percentage Dose Recovery (PDR) peak of &lt; 5.5%/hour. The data was collected and analyzed agnostic to the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing a High Risk Event Based on a 7.5 %/Hour Cut-off</measure>
    <time_frame>1 hour for MBT for assessment of this diagnostic outcome assessed during screening</time_frame>
    <description>Binary diagnosis of subjects that are at high risk to develop a deterioration event as determined by the Methacetin Breath Test (MBT) derived from an algorithm developed under other Exalenz clinical studies using a pre-designed cutoff of Percentage Dose Recovery (PDR) peak of &lt; 7.5%/hour.The data was collected and analyzed agnostic to the intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Decompensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Emricasan 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emricasan 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Methacetin Breath Test</intervention_name>
    <description>A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.</description>
    <arm_group_label>Emricasan 25mg</arm_group_label>
    <arm_group_label>Emricasan 5mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emricasan</intervention_name>
    <description>Investigational drug for NASH treatment in Main Conatus protocol</description>
    <arm_group_label>Emricasan 25mg</arm_group_label>
    <arm_group_label>Emricasan 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo versus emricasan in Conatus NASH treatment trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects 18 years or older, able to provide written informed consent&#xD;
             and able to understand and willing to comply with the requirements of the study.&#xD;
&#xD;
          2. Cirrhosis due to NASH with exclusion of other causes of cirrhosis (e.g. chronic viral&#xD;
             hepatitis, alcoholic liver disease, etc.)&#xD;
&#xD;
          3. At least one of the following: a) history of variceal hemorrhage (more than 3 months&#xD;
             prior to day 1) documented on endoscopy and requiring blood transfusion, b) history of&#xD;
             at least moderate ascites (on physical exam or imaging) currently treated with&#xD;
             diuretics.&#xD;
&#xD;
          4. MELD score ≥12 and ≤20 during screening&#xD;
&#xD;
          5. Albumin ≥2.5 g/dL during screening&#xD;
&#xD;
          6. Serum creatinine ≤1.5 mg/dL during screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of severe decompensation&#xD;
&#xD;
          2. Non-cirrhotic portal hypertension&#xD;
&#xD;
          3. Child-Pugh score ≥10&#xD;
&#xD;
          4. Current use of anticoagulants that affect prothrombin time or international normalized&#xD;
             ratio&#xD;
&#xD;
          5. ALT &gt;3 times upper limit of normal (ULN) or AST &gt;5 times ULN during screening&#xD;
&#xD;
          6. Initiation or discontinuation of non-selective beta blockers within 1 month of&#xD;
             screening&#xD;
&#xD;
          7. Transjugular intrahepatic portosystemic shunt or other porto-systemic bypass procedure&#xD;
             within 1 year of screening or previously requiring revision&#xD;
&#xD;
          8. Alpha-fetoprotein &gt;50 ng/mL in the last year&#xD;
&#xD;
          9. History of hepatocellular carcinoma (HCC) or evidence of HCC&#xD;
&#xD;
         10. History of malignancies other than HCC, unless successfully treated with curative&#xD;
             intent and believed to be cured&#xD;
&#xD;
         11. Prior liver transplant&#xD;
&#xD;
         12. Uncontrolled diabetes mellitus (HbA1c &gt;9%)&#xD;
&#xD;
         13. Change in diabetes medications or vitamin E within 3 months of screening&#xD;
&#xD;
         14. Restrictive bariatric surgery or bariatric device within 1 year of screening or prior&#xD;
             malabsorptive bariatric surgery&#xD;
&#xD;
         15. Symptoms of biliary colic unless resolved following cholecystectomy&#xD;
&#xD;
         16. History of significant alcohol consumption within the past 5 years&#xD;
&#xD;
         17. Current use of medications that are considered inhibitors of organic anion&#xD;
             transporting polypeptide OATP1B1 and OATP1B3 transporters&#xD;
&#xD;
         18. Prolongation of screening (pre-treatment) QTcF interval of &gt;500 msecs, or history or&#xD;
             presence of clinically concerning cardiac arrhythmias&#xD;
&#xD;
         19. Significant systemic or major illness other than liver disease&#xD;
&#xD;
         20. Human immunodeficiency virus infection&#xD;
&#xD;
         21. Use of alcohol, controlled substances (including inhaled or injected drugs), or&#xD;
             non-prescribed use of prescription drugs within 1 year of screening to the point of&#xD;
             interfering with the subject's ability to comply with study procedures and study drug&#xD;
             administration in the investigator's judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Florida Digestive Health Specialists Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <results_first_submitted>October 1, 2020</results_first_submitted>
  <results_first_submitted_qc>November 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2020</results_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03462576/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03462576/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>60 subjects were disqualified at baseline before being divided into arms due to screen failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients With Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm</title>
          <description>Arm 1. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 25 mg of Emricasan.</description>
        </group>
        <group group_id="P2">
          <title>Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm</title>
          <description>Arm 2. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 5 mg of Emricasan.</description>
        </group>
        <group group_id="P3">
          <title>Number of Subjects Experiencing a High Risk Event in Placebo Arm</title>
          <description>Arm 3. The number of subjects that experience a decompensation event as described in the protocol in the placebo arm .</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device Malfunction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm</title>
          <description>Arm 1. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 25 mg of Emricasan.</description>
        </group>
        <group group_id="B2">
          <title>Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm</title>
          <description>Arm 2. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 5 mg of Emricasan.</description>
        </group>
        <group group_id="B3">
          <title>Number of Subjects Experiencing a High Risk Event in Placebo Arm</title>
          <description>Arm 3. The number of subjects that experience a decompensation event as described in the protocol in the placebo arm .</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>1 subject's test was discontinued due to device malfunction.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.674" spread="9.307"/>
                    <measurement group_id="B2" value="60.875" spread="8.668"/>
                    <measurement group_id="B3" value="62.864" spread="7.135"/>
                    <measurement group_id="B4" value="61.1" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>1 subject test was discontinued due to device malfunction.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>1 subject test was discontinued due to device malfunction.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>1 subject test was discontinued due to device malfunction.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="44"/>
                    <count group_id="B4" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing a High Risk Event Based on a 5.5%/Hour Cut-off</title>
        <description>Binary diagnosis of subjects that are at high risk to develop a deterioration event as determined by the Methacetin Breath Test (MBT) derived from an algorithm developed under other Exalenz clinical studies using a pre-designed cutoff of Percentage Dose Recovery (PDR) peak of &lt; 5.5%/hour. The data was collected and analyzed agnostic to the intervention.</description>
        <time_frame>1 hour for MBT for assessment of this diagnostic outcome assessed during screening</time_frame>
        <population>The population analyzed is Intent to Diagnose (ITD)</population>
        <group_list>
          <group group_id="O1">
            <title>Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm</title>
            <description>Arm 1. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 25 mg of Emricasan.</description>
          </group>
          <group group_id="O2">
            <title>Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm</title>
            <description>Arm 2. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 5 mg of Emricasan.</description>
          </group>
          <group group_id="O3">
            <title>Number of Subjects Experiencing a High Risk Event in Placebo Arm</title>
            <description>Arm 3. The number of subjects that experience a decompensation event as described in the protocol in the placebo arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing a High Risk Event Based on a 5.5%/Hour Cut-off</title>
          <description>Binary diagnosis of subjects that are at high risk to develop a deterioration event as determined by the Methacetin Breath Test (MBT) derived from an algorithm developed under other Exalenz clinical studies using a pre-designed cutoff of Percentage Dose Recovery (PDR) peak of &lt; 5.5%/hour. The data was collected and analyzed agnostic to the intervention.</description>
          <population>The population analyzed is Intent to Diagnose (ITD)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Events in subjects below cut-off</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No event recorded in subjects below cut-off</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Events in subjects above cut-off</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No event recorded in subjects above cut-off</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing a High Risk Event Based on a 7.5 %/Hour Cut-off</title>
        <description>Binary diagnosis of subjects that are at high risk to develop a deterioration event as determined by the Methacetin Breath Test (MBT) derived from an algorithm developed under other Exalenz clinical studies using a pre-designed cutoff of Percentage Dose Recovery (PDR) peak of &lt; 7.5%/hour.The data was collected and analyzed agnostic to the intervention.</description>
        <time_frame>1 hour for MBT for assessment of this diagnostic outcome assessed during screening</time_frame>
        <population>The population analyzed is Intent to Diagnose (ITD).</population>
        <group_list>
          <group group_id="O1">
            <title>Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm</title>
            <description>Arm 1. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 25 mg of Emricasan.</description>
          </group>
          <group group_id="O2">
            <title>Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm</title>
            <description>Arm 2. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 5 mg of Emricasan.</description>
          </group>
          <group group_id="O3">
            <title>Number of Subjects Experiencing a High Risk Event in Placebo Arm</title>
            <description>Arm 3. The number of subjects that experience a decompensation event as described in the protocol in the placebo arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing a High Risk Event Based on a 7.5 %/Hour Cut-off</title>
          <description>Binary diagnosis of subjects that are at high risk to develop a deterioration event as determined by the Methacetin Breath Test (MBT) derived from an algorithm developed under other Exalenz clinical studies using a pre-designed cutoff of Percentage Dose Recovery (PDR) peak of &lt; 7.5%/hour.The data was collected and analyzed agnostic to the intervention.</description>
          <population>The population analyzed is Intent to Diagnose (ITD).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Events in subjects below cut-off</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No event recorded in subjects below cut-off</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Events in subjects above cut-off</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No event recorded in subjects above cut-off</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for a period of 48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm</title>
          <description>Arm 1. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 25 mg of Emricasan.</description>
        </group>
        <group group_id="E2">
          <title>Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm</title>
          <description>Arm 2. The number of subjects that experience a decompensation event as described in the protocol in the arm treated with 5 mg of Emricasan.</description>
        </group>
        <group group_id="E3">
          <title>Number of Subjects Experiencing a High Risk Event in Placebo Arm</title>
          <description>Arm 3. The number of subjects that experience a decompensation event as described in the protocol in the placebo arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Avrahm Hershkowitz/ Clinical Trial Manager</name_or_title>
      <organization>Exalenz Bioscience</organization>
      <phone>972-8-9737513</phone>
      <email>avrahamh@exalenz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

